Brian L. Hodous
Recludix Pharma (United States)(US)
Publications by Year
Research Areas
Fibroblast Growth Factor Research, Microtubule and mitosis dynamics, Cancer-related Molecular Pathways, Crystallization and Solubility Studies, X-ray Diffraction in Crystallography
Most-Cited Works
- → First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway(2015)313 cited
- → Enantioselective Staudinger Synthesis of β-Lactams Catalyzed by a Planar-Chiral Nucleophile(2002)245 cited
- → A precision therapy against cancers driven by KIT/PDGFRA mutations(2017)210 cited
- → Catalytic Asymmetric Staudinger Reactions to Form β-Lactams: An Unanticipated Dependence of Diastereoselectivity on the Choice of the Nitrogen Substituent(2005)190 cited
- → Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases(2019)137 cited
- → Enantioselective Addition of Alcohols to Ketenes Catalyzed by a Planar-Chiral Azaferrocene: Catalytic Asymmetric Synthesis of Arylpropionic Acids(1999)135 cited
- → Enantioselective Addition of Amines to Ketenes Catalyzed by a Planar-Chiral Derivative of PPY: Possible Intervention of Chiral Brønsted-Acid Catalysis(2002)132 cited
- → Preclinical Evaluation of AMG 900, a Novel Potent and Highly Selective Pan-Aurora Kinase Inhibitor with Activity in Taxane-Resistant Tumor Cell Lines(2010)119 cited
- → Evolution of a Highly Selective and Potent 2-(Pyridin-2-yl)-1,3,5-triazine Tie-2 Kinase Inhibitor(2007)91 cited
- → Discovery of Aminoquinazolines as Potent, Orally Bioavailable Inhibitors of Lck: Synthesis, SAR, and in Vivo Anti-Inflammatory Activity(2006)67 cited